Baxter completed the acquisition of Hillrom for $10.5bn.

Baxter, a firm that develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, completed the acquisition of Hillrom, a medical technology company, for $10.5bn. The Baxter-Hillrom combination unlocks the next phase of our transformation, presenting a new wave of potential to drive greater impact for patients, clinicians, employees, shareholders and other communities we serve worldwide. Integrating our complementary capabilities introduces additional opportunities for growth across our broad geographic footprint and also creates remarkable new possibilities for connectivity with leading-edge digital health innovation focused on enhancing care, lowering costs and increasing workflow efficiency," José E. Almeida, Baxter Chairman, President and CEO.